A Phase I Study of ECO-4601 in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the maximum tolerated dose (MTD) and the
recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for
14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid
tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This
study was also designed to determine the clinical pharmacokinetic profile, safety of multiple
cycles of administration, and document the antitumor activity of ECO-4601.